Categories AlphaGraphs, Analysis, Health Care

Bristol-Myers Squibb reports Q4 earnings on Jan 24. What to expect

Only two weeks after announcing its massive acquisition of Celgene Corporation, drug-maker Bristol-Myers Squibb (BMY) is all set to report fourth-quarter results on Thursday, January 24.

Analysts expect the company to post earnings of 85 cents per share on a top-line of $5.98 billion during the fourth quarter. During the same period last year, the company had reported earnings of 68 cents per share on revenues of $5.4 billion.

The stock has mostly underperformed in the trailing 52 weeks, declining almost 9%, while the industry recorded a modest growth of 7%.

Bristol-Myers Squibb year over year product sales growth

Throughout last year, its flagship drug – Opdivo – struggled in the cut-throat competition in the oncology market. Despite strong demand, Opdivo, which accounts for about one-fourth of Bristol Myers’ total sales, faced stiff competition from rival Merck’s (MRK) Keytruda.

In the recent quarters though, thanks to a slew of regulatory approvals, Opdivo has been picking up in sales and the fourth quarter figures of the immuno-oncology drug will play a key role in deciding the trading direction.

During the prior- reported quarter, Opdivo outgrew its cardiovascular drug Eliquis in a rare instance. Eliquis is also meanwhile perceived as a growth driver for the company, delivering 35% sales growth in the first nine months. Market observers are expecting this growth trajectory to continue into the fourth quarter.

The top line is likely to get a boost from the label expansion of these products.

In a massive deal, Eli Lilly acquires Loxo Oncology

Also, keep a lookout for management comments on the recent purchase of Celgene during the earnings conference call. The transcript of the entire call will be available here.

On January 3, Bristol-Myers had said that it was acquiring Celgene in a $74-billion cash-and-stock transaction. Shares of Celgene jumped over 30% in the pre-market trading hours following the announcement, while Bristol-Myers Squibb shares plunged about 13%.

 

Listen to publicly listed companies’ earnings conference calls along with the edited closed caption text 

Most Popular

Does Unity Software (U) stock has more room to run?

Last month, the IPO market was in a full swing. IPOs of Snowflake (NYSE: SNOW) and JFROG (NASDAQ: FROG) had an impressive opening day in September, the former creating a

PepsiCo (PEP): Steady snacking habits amid pandemic drive strong quarter for beverage giant

PepsiCo Inc. (NASDAQ: PEP) beat market expectations on both revenue and earnings for the third quarter of 2020. The company saw the momentum continue in its snacks business while the

Does the virus-driven boom make Electronic Arts (EA) a good investment?

With more and more people turning to virtual entertainment sources, amid the virus-related movement restrictions, video game publishers like Electronic Arts (NASDAQ: EA) are witnessing unusually high demand. Not surprisingly,

2 thoughts on “Bristol-Myers Squibb reports Q4 earnings on Jan 24. What to expect

  1. Pingback: viagra online

Leave a Reply

Your email address will not be published. Required fields are marked *

Add Comment
Loading...

Cancel
Viewing Highlight
Loading...
Highlight
Close
Top